GlassScriptPhysician profile
Luisa Vega
NPI 1558772657
$29,576.55
in general payments reported to CMS, 2019-2025
10 companies · $27K in 2025
The $27K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,056 · 2022: $383 · 2023: $552 · 2024: $516 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Food and Beverage: $3,019 · Travel and Lodging: $1,727 · Education: $79.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,311.50 |
| Food and Beverage | $3,019.07 |
| Travel and Lodging | $1,727.04 |
| Education | $79.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $14,152.00 | 2021-2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $13,402.90 | 2023-2025 | Rexulti, Nuedexta |
| Avanir Pharmaceuticals, INC. | $1,011.03 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $399.72 | 2024-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $199.04 | 2023-2025 | Austedo Xr, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $129.21 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $121.40 | 2025 | Cobenfy |
| Bioxcel Therapeutics, INC. | $116.63 | 2024 | Igalmi |
| Indivior INC. | $22.34 | 2025 | Sublocade |
| Sunovion Pharmaceuticals INC. | $22.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luisa Vega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.